Supira Medical Funding Round Will Support Development of Its Percutaneous Ventricular Assist Device

February 28, 2022—Supira Medical, Inc., a Shifamed portfolio company developing a next-generation solution for temporary mechanical circulatory support, announced the closing of $30 million in Series C financing. The funds will be used to finalize product development and initiate a first-in-human clinical study for the company’s high-flow, low-profile percutaneous ventricular assist device (pVAD).

The pVAD will provide temporary mechanical support during stent placement or angioplasty in high-risk patients with severe coronary artery disease or comorbidities. Additionally, the device will treat patients experiencing cardiogenic shock.

According to the company, the financing was led by Cormorant Asset Management and The Capital Partnership, with participation from 415 Capital, Amed Ventures, PA MedTech VC Fund, and Shifamed angel investors.